Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma

被引:75
作者
Ito, Y
Takeda, T
Sasaki, Y
Sakon, M
Yamada, T
Ishiguro, S
Imaoka, S
Tsujimoto, M
Higashiyama, S
Monden, M
Matsuura, N
机构
[1] Osaka Univ, Fac Med, Sch Allied Hlth Sci, Dept Pathol, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Fac Med, Sch Allied Hlth Sci, Dept Biochem, Suita, Osaka 5650871, Japan
[3] Osaka Seamens Insurance Hosp, Dept Surg, Osaka, Japan
[4] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Surg, Osaka, Japan
[5] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Pathol, Osaka, Japan
[6] Osaka Univ, Sch Med, Dept Surg 2, Osaka, Japan
[7] Osaka Police Hosp, Dept Pathol, Osaka, Japan
关键词
erbB receptor family; cholangiocellular carcinoma; immunohistochemistry;
D O I
10.1078/0344-0338-00016
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The type I family of growth factor receptors is known to play a role in the development of several carcinomas, but its role in hepatic malignancies is not clearly understood. In this study we investigated the expression of this family of EGF-R, c-erbB-2, c-erbB-3 and c-erbB-4 in 38 intrahepatic cholangiocellular carcinomas (CCC) by means of immunohistochemistry. EGF-R expression was related to lymph node metastasis, aberrant p53 expression, proliferating activity, and carcinoma differentiation. c-erbB-2 expression was observed in more than 50% of the cases, but was not related to any clinicopathological features. c-erbB-3 expression was linked to lymph node metastasis, and c-erbB-4 expression was directly related to proliferating activity and lymph node metastasis. These results indicate that: 1) EGF-R contributes greatly to CCC progression, and c-erbB-3 and c-erbB-4 have roles similar to but less than that of EGFR, and 2) c-erbB-2 is expressed in CCC in high incidence, but its clinical role in CCC remains unclear.
引用
收藏
页码:95 / 100
页数:6
相关论文
共 32 条
[1]   c-erbB-3 protein expression in ductal carcinoma in situ of the breast [J].
Bobrow, LG ;
Millis, RR ;
Happerfield, LC ;
Gullick, WJ .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (11) :1846-1850
[2]  
Bodey B, 1997, ANTICANCER RES, V17, P1319
[3]  
BRUNT EM, 1992, AM J CLIN PATHOL, V97, pS53
[4]   ONCOGENES AND SIGNAL TRANSDUCTION [J].
CANTLEY, LC ;
AUGER, KR ;
CARPENTER, C ;
DUCKWORTH, B ;
GRAZIANI, A ;
KAPELLER, R ;
SOLTOFF, S .
CELL, 1991, 64 (02) :281-302
[5]   Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma - An immunohistochemical study [J].
Chow, NH ;
Liu, HS ;
Yang, HB ;
Chan, SH ;
Su, IJ .
VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY, 1997, 430 (06) :461-466
[6]   C-ERBB-2 ONCOGENE EXPRESSION IN HEPATOCELLULAR-CARCINOMA AND CHOLANGIOCARCINOMA [J].
COLLIER, JD ;
GUO, K ;
MATHEW, J ;
MAY, FEB ;
BENNETT, MK ;
CORBETT, IP ;
BASSENDINE, MF ;
BURT, AD .
JOURNAL OF HEPATOLOGY, 1992, 14 (2-3) :377-380
[7]  
FUKUSATO T, 1990, ACTA PATHOL JAPON, V40, P22
[8]  
Haugen DRF, 1996, CANCER RES, V56, P1184
[9]  
Ibrahim SO, 1997, ANTICANCER RES, V17, P4539
[10]   A new monoclonal antibody which selectively recognizes the active form of Src tyrosine kinase [J].
Kawakatsu, H ;
Sakai, T ;
Takagaki, Y ;
Shinoda, Y ;
Saito, M ;
Owada, MK ;
Yano, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (10) :5680-5685